Airsonett appoints Senior Medical Director to better meet the increased interest in Airsonett from the health care sector
The Swedish product Airsonett is an asthma treatment which provides the patient with an allergen free environment during the night’s sleep. Clinical trials show that Airsonett treatment improves the allergy, decreases the airway inflammation and increases the quality of life – all without side effects. As more and more positive evaluations of Airsonett treatment have been published, the support and interest from both Swedish and international Health Care Authorities and organizations have increased dramatically. The company is now expanding its organization to better meet this increased need for knowledge and support.
Ann-Marie Tindberg recently took up the position as Senior Medical Director at Airsonett and her mission is to develop Airsonett’s medical expertise focusing on generating supporting clinical evidence for the company’s product. Ann-Marie holds an MSc in Pharmacy and has 25 years’ experience from the pharmaceutical industry. She has more than 15 years’ experience on an international level as, among other positions, Global Medical Affairs Manager at AstraZeneca Respiratory and Senior International Medical Advisor at Nycomed. Ann-Marie was most recently Director Compliance at Takeda where she primarily worked with issues related to the ethical regulatory framework in Europe for the pharmaceutical industry.
”Over the years, we have invested heavily in clinical studies to provide evidence that Airsonett in an effective treatment for patients with allergic asthma. This investment continues and we have a number of on-going studies where the effect of Airsonett for patients with allergic asthma is further explored but also for patients with severe allergic eczema. Our clinical data is very well received both in Sweden and internationally so a Senior Medical Director is needed to strengthen our organization. I am very pleased that Ann-Marie, with her long, international experience from the asthma and allergy field has chosen to work for us.” says Fredrik Werner, CEO, Airsonett.
Airsonett markets a treatment for patients with atopic (allergic) asthma who, in spite of taking asthma medication, still has poorly controlled asthma. The treatment has no side effects. The Airsonett treatment ensures that the patient sleeps in clean air. Studies show that Airsonett inhibits the allergy, reduces the inflammation and improves quality of life.
FOR MORE INFORMATION, PLEASE CONTACT:
Fredrik Werner, CEO, Airsonett AB
Tel: +46 (0)708 494 862 E-mail: fredrik.werner@airsonett.com